Kyprolis (Carfilzomib) for amyloidosis

Overview
Kyprolis is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory multiple myeloma who have already received one to three lines of therapy. Kyprolis is sometimes prescribed off-label to treat amyloidosis. Kyprolis is also referred to by its drug name, carfilzomib.

Kyprolis is used as a targeted therapy for amyloidosis. Kyprolis is a member of a class of drugs called proteasome inhibitors. Kyprolis is believed to work by targeting proteasomes inside abnormal cells, keeping them from digesting and discarding unwanted proteins. These proteins then build up in the abnormal cells, which leads to cell death.

How do I take it?
Prescribing information states that Kyprolis is given as an intravenous infusion (slow injection into a vein) by a health care professional. Kyprolis is usually given in a health clinic or doctor’s office. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Kyprolis lists common side effects that include fatigue, diarrhea, nausea, difficulty breathing, fever, headache, cough, edema (swelling), thrombocytopenia (low blood platelet count), and anemia (low red blood cell count).

Serious side effects listed for Kyprolis include heart failure, kidney failure, acute respiratory failure, severe difficulty breathing, severe hypertension (high blood pressure), hemorrhage (bleeding), liver damage, liver failure, and fetal harm.

For more details about this treatment, visit:
Kyprolis — Amgen
What Is Kyprolis? — Multiple Myeloma Research Foundation